EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

The clinical use of cryoprecipitate and fibrinogen concentrate: A scoping review

Aaron S Hess, Sandra K White, Elizabeth P Crowe iD, Jay S Raval, Jennifer Andrews iD, Claudia S Cohn iD, Mischa L Covington iD, Melissa M Cushing iD, Cyril Jacquot iD, Jenna Khan, Anil K Panigrahi, Nabiha H Saifee iD und 4 weitere

Transfusion · 2026-07 · 66 (7) · 1424-1437

DOI: 10.1111/trf.70255 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Transfusion, online erschienen am 19.05.2026. Verfasst von Aaron S Hess und 15 weiteren Autor:innen. Beteiligte Einrichtung: New Zealand Blood Service, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Fibrinogen, Factor VIII, Afibrinogenemia, Hemorrhage. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AABB Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acquired hypofibrinogenemia poses significant bleeding risks. Concentrated sources of fibrinogen, whether cryoprecipitate or fibrinogen concentrates, are widely used. This scoping review aimed to identify and map the available evidence on fibrinogen supplementation. Study Design and Methods We used the JBI Manual and PRISMA‐ScR guidelines. We included patients of all ages treated with fibrinogen supplementation. The concept was treatment with cryoprecipitate or fibrinogen concentrate (prophylactically or therapeutically); and context was any clinical setting worldwide. Eligible studies included randomized trials and observational studies with comparator arms. Comprehensive searches of three databases were performed on February 21, 2025. Primary studies meeting inclusion criteria were selected. UpSet data visualizations displayed studies with intersecting sets of characteristics.

Results

From 8181 references screened, 134 met inclusion criteria, of which 61 were randomized trials and 16 propensity‐matched observational cohort studies. The highest proportion of trials focused on cardiovascular surgery (28/61; 46%) then trauma (12/61; 20%) populations and mainly assessed use of fibrinogen therapeutically (34/61; 56%). More trials evaluated fibrinogen concentrate (53/61; 87%) compared to cryoprecipitate (8/61; 13%). Commonly reported outcomes included bleeding, transfusion needs, or mortality. Studies inconsistently reported dosing, timing, and definitions of hypofibrinogenemia. Studies evaluating certain key populations—including obstetrics and pediatrics—were limited. All but one propensity‐matched study was in either cardiovascular surgery or trauma.

Discussion

There is a growing body of literature informing use of fibrinogen supplementation, particularly in cardiovascular surgery and trauma populations. Meta‐analyses appear feasible to inform evidence‐based guideline development; however, variability in dosing, timing, and definitions highlights the need for more harmonized research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrinogenFactor VIIIAfibrinogenemiaHemorrhageHumansRandomized Controlled Trials as Topic

Substanzen

FibrinogenFactor VIIIcryoprecipitate coagulum

Autor:innen und Institutionen

  • New Zealand Blood Service, Christchurch, New Zealand.
  • Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
  • Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont, USA.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Elizabeth P Crowe, Jennifer Andrews, Claudia S Cohn, Mischa L Covington, Melissa M Cushing, Cyril Jacquot, Nabiha H Saifee, Aaron A R Tobian, Mary M McFarland, Simon J Stanworth, Ryan A Metcalf

Förderung

  • AABB Foundation

Zitieren

APA

Hess, A. S., White, S. K., Crowe, E. P., Raval, J. S., Andrews, J., Cohn, C. S., Covington, M. L., Cushing, M. M., Jacquot, C., Khan, J., Panigrahi, A. K., Saifee, N. H., Tobian, A. A. R., McFarland, M. M., Stanworth, S. J., & Metcalf, R. A. (2026). The clinical use of cryoprecipitate and fibrinogen concentrate: A scoping review. Transfusion, 66(7), 1424-1437. https://doi.org/10.1111/trf.70255

Vancouver

Hess AS, White SK, Crowe EP, Raval JS, Andrews J, Cohn CS, et al. The clinical use of cryoprecipitate and fibrinogen concentrate: A scoping review. Transfusion. 2026;66(7):1424-1437. doi:10.1111/trf.70255

BibTeX
@article{Hess2026,
  author = {Hess, Aaron S and White, Sandra K and Crowe, Elizabeth P and Raval, Jay S and Andrews, Jennifer and Cohn, Claudia S and Covington, Mischa L and Cushing, Melissa M and Jacquot, Cyril and Khan, Jenna and Panigrahi, Anil K and Saifee, Nabiha H and Tobian, Aaron A R and McFarland, Mary M and Stanworth, Simon J and Metcalf, Ryan A},
  title = {The clinical use of cryoprecipitate and fibrinogen concentrate: A scoping review},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {7},
  pages = {1424--1437},
  doi = {10.1111/trf.70255}
}
Kostenlos starten →